Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

Abstract Background Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission. Asciminib is the only approved BCR::ABL1 inhibitor that Specifically Targets the ABL My...

Full description

Saved in:
Bibliographic Details
Main Authors: Timothy P. Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Cardoso, Becki Nieman, Sara Quenet, Jorge E. Cortes
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Journal of Hematology & Oncology
Subjects:
ASC4MORE
CML
Asciminib
Tyrosine kinase inhibitors
Deep molecular response
Imatinib
Online Access:https://doi.org/10.1186/s13045-024-01642-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13045-024-01642-6

Similar Items